Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BDR 231

Next Previous
Drug Profile

BDR 231

Alternative Names: BDR-231

Latest Information Update: 02 Nov 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MDimune
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease; Inflammation

Most Recent Events

  • 14 Oct 2022 Preclinical trials in Inflammation in South Korea (Parenteral) (MDimune pipeline, October 2022)
  • 23 Jun 2022 BDR 231 is available for licensing as of 23 Jun 2022. http://www.mdimune.com/en/m21.php
  • 22 Jun 2022 MDimune has patent protection for BioDrone® in USA, Europe, Japan, Korea and China before June 2022 (MDimune pipeline, June 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top